Mineralys Q2 net loss $241M; lorundrostat PDUFA Dec 22, 2026; new CMO appointed

Mineralys Therapeutics, Inc.

Q2 2026 net loss $241.1M vs $43.3M in Q2 2025; R&D $221.4M incl $200M Tanabe upfront payment.
Cash $661.4M at June 30; raised ~$150M offering and drew $100M tranche of $500M Pharmakon loan.
FDA PDUFA target date Dec 22, 2026 for lorundrostat NDA; commercial launch preparations on track.
Amended Tanabe license: $200M paid to eliminate royalties; remaining milestones up to $255M.
Appointed Dr. Terry Ferguson CMO effective Aug 10; David Rodman stays as Strategic Advisor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.